




RealRate

PHARMACEUTICAL 2020

Biostax Corp.
Rank 341 of 358





PHARMACEUTICAL 2020

Biostax Corp.
Rank 341 of 358



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 330% points. The greatest weakness of Biostax Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 204% points.

The company's Economic Capital Ratio, given in the ranking table, is -393%, being 430% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	4.9
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,694
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	133
Other Liabilities	0
Other Net Income	-559
Other Revenues	0
Property and Equipment	0.69
Research and Development	336
Selling, General and Administrative Expense	2,368

Output Variable	Value in 1000 USD
Assets	5.8
Liabilities	13,694
Expenses	2,838
Revenues	0
Stockholders Equity	-13,689
Net Income	-3,397
Comprehensive Net Income	-3,397
Economic Capital Ratio	-393%